SCHEMBL6071247

SCHEMBL6071247

CC(C)CNC(=O)c1ccc2[nH]c3c(c2c1)CCCC3=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.58
MAPT P10636 4/20 0.58
HSD17B10 Q99714 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
ALOX15 P16050 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 7/20 0.56
LMNA P02545 5/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 4/20 0.54
TP53 P04637 1/20 0.52
CASP1 P29466 1/20 0.52
GAA P10253 2/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
RAB9A P51151 1/20 0.45
PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583283 0.83 MAPK10 (0.52) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL5461815 0.82 IMPDH2 (0.57) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL6070647 0.79 KDM4E (0.72) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL6070963 0.79 MAPT (0.45) KDM4EMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6070960 0.79 MAPT (0.45) KDM4EMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL3001898 0.78 KDM4E (0.64) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL6070517 0.78 MAPK10 (0.56) KDM4EMAPTHSD17B10ALOX15ALDH1A1
SCHEMBL3001693 0.77 MAPKAPK2 (0.56) KDM4EMAPTHSD17B10SMN1; SMN2ALOX15
SCHEMBL25334888 0.76 TP53 (0.71) KDM4EMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL32680076 0.76 TP53 (0.71) KDM4EMAPTSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 KDM4E 1799/4885MAPT 639/4885HSD17B10 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.